Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P07327
UPID:
ADH1A_HUMAN
Alternative names:
Alcohol dehydrogenase subunit alpha
Alternative UPACC:
P07327; A8K3E3; Q17R68
Background:
Alcohol dehydrogenase 1A, also known as Alcohol dehydrogenase subunit alpha, plays a crucial role in metabolizing alcohols in the body, including the oxidation of primary and secondary alcohols. Despite ethanol being a poor substrate, this enzyme's activity is pivotal in alcohol metabolism, as highlighted in research (PubMed:2738060).
Therapeutic significance:
Understanding the role of Alcohol dehydrogenase 1A could open doors to potential therapeutic strategies. Its critical function in alcohol metabolism positions it as a key target for addressing alcohol-related disorders.